Low Dose Alternating Current Technology (LDAC)

The LDAC prostate cancer treatment device delivers its low dose electric field to the treatment space through a needle array inserted directly into the prostate in a similar way to brachytherapy, except that the LDAC needle array delivers energy instead of planting radioactive seeds. The needle array creates a “field of treatment” that encompasses the entire prostate and allows LDAC to deliver its cancer killing energy to the whole prostate gland.

LaZure Scientific, Inc. was formed in 2006 for the purpose of developing and commercializing LDAC, a proprietary, preferential cancer treatment technology. Based on the results of 17 pre-clinical studies that demonstrate LDAC’s preferential cancer killing ability, an investigational use only clinical device for early stage prostate cancer treatment has been developed. The Company's first-in-man study is currently underway in the Republic of Georgia.